TY - JOUR
T1 - Pseudomonas aeruginosa Soluble Pyocins as Antibacterial Weapons
AU - Cornelis, Pierre
AU - Dingemans, Jozef
AU - Baysse, Christine
N1 - © 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2024
Y1 - 2024
N2 - Pseudomonas aeruginosa is an opportunistic pathogen causing nosocomial infections and associated with lung infections in cystic fibrosis (CF) patients (Lyczak et al., Microbes Infect 2:1051-1060, 2000). Multiple drug-resistant P. aeruginosa strains pose a serious problem because of antibiotic treatment failure. There is therefore a need for alternative anti-Pseudomonas molecules. Soluble pyocins (S-pyocins) are bacteriocins produced by P. aeruginosa strains that kill sensitive strains of the same species. These bacteriocins and their immunity gene are easily cloned and expressed in E. coli and their activity spectrum against different P. aeruginosa strains can be tested. In this chapter, we describe the procedures for cloning, expression, and sensitivity testing of two different S-pyocins. We also describe how to identify their receptor binding domain in sensitive strains, how to construct chimeric pyocins with extended activity spectra, and how to identify new pyocins in genomes by multiplex PCR.
AB - Pseudomonas aeruginosa is an opportunistic pathogen causing nosocomial infections and associated with lung infections in cystic fibrosis (CF) patients (Lyczak et al., Microbes Infect 2:1051-1060, 2000). Multiple drug-resistant P. aeruginosa strains pose a serious problem because of antibiotic treatment failure. There is therefore a need for alternative anti-Pseudomonas molecules. Soluble pyocins (S-pyocins) are bacteriocins produced by P. aeruginosa strains that kill sensitive strains of the same species. These bacteriocins and their immunity gene are easily cloned and expressed in E. coli and their activity spectrum against different P. aeruginosa strains can be tested. In this chapter, we describe the procedures for cloning, expression, and sensitivity testing of two different S-pyocins. We also describe how to identify their receptor binding domain in sensitive strains, how to construct chimeric pyocins with extended activity spectra, and how to identify new pyocins in genomes by multiplex PCR.
KW - Humans
KW - Pyocins/pharmacology
KW - Pseudomonas aeruginosa/metabolism
KW - Escherichia coli/metabolism
KW - Bacteriocins/metabolism
KW - Anti-Bacterial Agents/chemistry
KW - Pseudomonas Infections/drug therapy
UR - http://www.scopus.com/inward/record.url?scp=85174751129&partnerID=8YFLogxK
U2 - 10.1007/978-1-0716-3473-8_9
DO - 10.1007/978-1-0716-3473-8_9
M3 - Article
C2 - 37819519
SN - 1064-3745
VL - 2721
SP - 125
EP - 136
JO - Methods in molecular biology (Clifton, N.J.)
JF - Methods in molecular biology (Clifton, N.J.)
ER -